Literature DB >> 10381512

Kozak sequence polymorphism of the glycoprotein (GP) Ibalpha gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex.

V Afshar-Kharghan1, C Q Li, M Khoshnevis-Asl, J A López.   

Abstract

Despite the known importance of the sequences surrounding ATG start codons (Kozak sequences) for efficient translation of proteins, few reports have appeared that describe the natural variations in these sequences. Here, we report a human polymorphism in the Kozak sequence of the platelet adhesion receptor, glycoprotein (GP) Ibalpha, a component of the GP Ib-IX-V complex, which mediates the initial adhesion of platelets to the blood vessel wall following injury. The polymorphism is based on the presence of either thymine (T) or cytosine (C) at position -5 from the initiator ATG in the GP Ibalpha gene. The less common allele, -5C, represented 8% to 17% of the alleles in four ethnic populations surveyed. This allele more closely resembles the sequence considered optimal for efficient initiation of protein translation and is associated with increased expression of the receptor on the cell membrane, both in transfected cells and in the platelets of individuals carrying the allele. In vitro transcription/translation studies indicate that the increased expression results from more efficient translation of the -5C form of the GP Ibalpha mRNA. Other mutations made to approximate more closely the consensus sequence described by Kozak did not increase expression of the receptor. This is the first known description of Kozak sequence polymorphism as a determinant of the surface levels of a cell adhesion receptor. This polymorphism may influence an individual's susceptibility for the development of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381512

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 2.  Role of platelet glycoprotein polymorphisms in cardiovascular diseases.

Authors:  Christian Meisel; José A López; Karl Stangl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-12       Impact factor: 3.000

Review 3.  The genetics of normal platelet reactivity.

Authors:  Thomas J Kunicki; Diane J Nugent
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

4.  Platelet membrane glycoprotein Ibalpha gene -5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis.

Authors:  H Douglas; K Michaelides; D A Gorog; E Durante-Mangoni; N Ahmed; G J Davies; E G D Tuddenham
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

Review 5.  The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Authors:  Yao Yang; Joshua P Lewis; Jean-Sébastien Hulot; Stuart A Scott
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-07-14       Impact factor: 4.481

6.  Novel Mutation in Bernard-Soulier Syndrome.

Authors:  Kirstin Sandrock; Ralf Knöfler; Andreas Greinacher; Birgitt Fürll; Sebastian Gerisch; Ulrich Schuler; Siegmund Gehrisch; Anja Busse; Barbara Zieger
Journal:  Transfus Med Hemother       Date:  2010-09-15       Impact factor: 3.747

7.  Bone mass pharmacogenetics and ethnic health implications.

Authors:  Francesco Massart; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2007-05

8.  Platelet glycoprotein Ibalpha gene polymorphism and massive or submassive pulmonary embolism.

Authors:  Ahmet Soylu; Mehmet Tokaç; Tülin Cora; Mehmet Akif Düzenli; Hasan Acar
Journal:  J Thromb Thrombolysis       Date:  2008-02-19       Impact factor: 2.300

9.  Genetic variation responsible for mouse strain differences in integrin alpha 2 expression is associated with altered platelet responses to collagen.

Authors:  Tong-Tong Li; Susana Larrucea; Shiloe Souza; Suzanne M Leal; José A López; Edward M Rubin; Bernhard Nieswandt; Paul F Bray
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

10.  Platelet GPIbalpha, GPIV and vWF polymorphisms and fatal pre-hospital MI among middle-aged men.

Authors:  Minna Pellikka; Lassi Narhi; Markus Perola; Antti Penttila; Pekka J Karhunen; Jussi Mikkelsson
Journal:  J Thromb Thrombolysis       Date:  2007-07-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.